View Post

AIVITA Completes Treatment of First Patient in Phase 2 Ovarian Cancer Trial

In Clinical Trials by Barbara Jacoby

Source: AIVITA Biomedical, Inc. From: prnewswire.com AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today that its first patient has completed treatment in its multi-center Phase 2 ROOT OF CANCER ovarian cancer trial. The patient has received the eighth and final dose of the study therapy under the guidance of Principal Investigator Dr. Lisa Abaid …

View Post

OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer

In Clinical Trials by Barbara Jacoby

Source: OncoQuest, Inc. From: prnewswire.com OncoQuest Inc., a privately held, cancer immunotherapy company, has retained the services of IQVIA, a company formed through the merger of IMS Health and Quintiles, to manage OncoQuest’s planned Phase 3 clinical study in frontline ovarian cancer with the company’s lead product candidate, oregovomab, an anti-CA-125 antibody. OncoQuest will collaborate with IQVIA, a leading global …

View Post

Breast Cancer Drug Promising in Phase 3 Trial

In Clinical Trials by Barbara Jacoby

By: Steven Reinberg From: consumer.healthday.com For women with advanced breast cancer who carry the BRCA1 and BRCA2 gene mutations, an experimental drug could improve survival, a new study suggests. The BRCA mutations are linked with a greater risk for aggressive breast and ovarian cancer. The drug, talazoparib, works by blocking an enzyme called poly ADP ribose polymerase (PARP), thus preventing …

View Post

Olaparib Extends PFS in Ovarian Cancer in SOLO-1 Clinical Trial

In Clinical Trials by Barbara Jacoby

By: Sarah Tilyou From: clinicaloncology.com Maintenance therapy with olaparib can reduce the risk for ovarian cancer progression and related death by 70% at three years, according to results of the phase 3 SOLO-1 trial.  The findings, which were presented at the ESMO 2018 Congress (abstract LBA7_PR) and published in The New England Journal of Medicine (2018 Oct 21. [Epub ahead …

View Post

Could even more cancer patients benefit from PARP inhibitors?

In In The News by Barbara Jacoby

By: Arlene Weintraub From: fiercebiotech.com PARP inhibitors like AstraZeneca’s Lynparza and Tesaro’s Zejula have revolutionized the treatment of ovarian cancers with BRCA mutations and are starting to take off in breast cancer treatment too. But the way that these drugs work could make them applicable to many more cancer types, some oncology researchers believe. The latest evidence of that comes from Yale University, …

View Post

Potential new strategy to fight ovarian cancer found

In In The News by Barbara Jacoby

From: bcm.edu A new discovery opens the possibility of developing a novel way to fight ovarian cancer. Researchers at Baylor College of Medicine and the University of Texas MD Anderson Cancer Center have revealed a previously unknown cellular pathway that selectively regulates a mutant protein, called p53-R175H, linked to ovarian cancer growth. The researchers identified a key regulator of this …

View Post

‘Chemo Bath’ Offers New Hope For Cancer Patients

In In The News by Barbara Jacoby

Filed Under:  Chemotherapy, Kristine Johnson, Local TV From: cbslocal.com A diagnosis of stage four ovarian cancer can be devastating, but imagine being told it’s a death sentence. It happened to one local woman, but an experimental procedure not only gave her hope — it saved her life. Isabel Navas now has countless holidays to look forward to, but just over …

View Post

Doctors Said Immunotherapy Would Not Cure Her Cancer. They Were Wrong.

In In The News by Barbara Jacoby

By: Gina Kolata From: nytimes.com No one expected the four young women to live much longer. They had an extremely rare, aggressive and fatal form of ovarian cancer. There was no standard treatment. The women, strangers to one another living in different countries, asked their doctors to try new immunotherapy drugs that had revolutionized treatment of cancer. At first, they …

View Post

Immunotherapy trial treatment getting results for cancer patients

In In The News by Barbara Jacoby

By: Kirstin O’Connor From: clickorlando.com Florida Hospital first site in nation for clinical trial Karen Bierer was given two years to live after she was diagnosed with ovarian cancer. The 70-year-old is one of nearly 21,000 women in the U.S. diagnosed with the deadly disease every year, according to the Centers for Disease Control and Prevention. Chemotherapy and radiation were nothing new …

View Post

Risk of developing cancer from the ‘Angelina Jolie gene’ depends entirely on family history, major study finds

In In The News by Barbara Jacoby

By: Stephen Matthews From: dailymail.co.uk The exact risk of developing cancer from having the ‘Angelina Jolie gene’ depends on family history, major new analysis shows. BRCA mutations, made famous by the Hollywood actress who was a carrier, are known to heighten the chance of developing the deadly disease. But before now, scientists were unable to provide an accurate percentage for …